Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Retained Earnings (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Retained Earnings for 7 consecutive years, with -$1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 41.27% to -$1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 billion, a 41.27% decrease, with the full-year FY2025 number at -$1.1 billion, down 41.27% from a year prior.
  • Retained Earnings was -$1.1 billion for Q4 2025 at Kymera Therapeutics, down from -$979.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$13000.0 in Q1 2021 to a low of -$1.1 billion in Q4 2025.
  • A 5-year average of -$370.4 million and a median of -$327.4 million in 2022 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 99.49% in 2021; the steepest drop was 118852.44% in 2021.
  • Kymera Therapeutics' Retained Earnings stood at -$660000.0 in 2021, then crashed by 58050.0% to -$383.8 million in 2022, then crashed by 38.29% to -$530.8 million in 2023, then tumbled by 42.18% to -$754.6 million in 2024, then plummeted by 41.27% to -$1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Retained Earnings are -$1.1 billion (Q4 2025), -$979.0 million (Q3 2025), and -$896.8 million (Q2 2025).